ATE259650T1 - Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen - Google Patents
Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinenInfo
- Publication number
- ATE259650T1 ATE259650T1 AT96926873T AT96926873T ATE259650T1 AT E259650 T1 ATE259650 T1 AT E259650T1 AT 96926873 T AT96926873 T AT 96926873T AT 96926873 T AT96926873 T AT 96926873T AT E259650 T1 ATE259650 T1 AT E259650T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- lipids
- preparations
- reducing
- blood levels
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000001130 gallstones Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51626395A | 1995-08-17 | 1995-08-17 | |
| PCT/US1996/012674 WO1997006816A1 (en) | 1995-08-17 | 1996-08-02 | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE259650T1 true ATE259650T1 (de) | 2004-03-15 |
Family
ID=24054813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96926873T ATE259650T1 (de) | 1995-08-17 | 1996-08-02 | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20020147142A1 (de) |
| EP (1) | EP0865294B1 (de) |
| JP (1) | JP4173913B2 (de) |
| AT (1) | ATE259650T1 (de) |
| AU (1) | AU6688896A (de) |
| CA (1) | CA2229450A1 (de) |
| DE (1) | DE69631605T2 (de) |
| DK (1) | DK0865294T3 (de) |
| ES (1) | ES2216055T3 (de) |
| MX (1) | MX9801159A (de) |
| PT (1) | PT865294E (de) |
| WO (1) | WO1997006816A1 (de) |
| ZA (1) | ZA966798B (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| CA2224867A1 (en) * | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| US5830450A (en) * | 1996-06-19 | 1998-11-03 | Lallone; Roger L. | Compositions of leptin bound to an apolipoprotein |
| US7332338B2 (en) | 1996-10-04 | 2008-02-19 | Lexicon Pharmaceuticals, Inc. | Vectors for making genomic modifications |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
| US6436707B1 (en) | 1998-03-27 | 2002-08-20 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
| US6808921B1 (en) | 1998-03-27 | 2004-10-26 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| JP4199421B2 (ja) * | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| CA2388417A1 (en) * | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| JP2005506994A (ja) | 2001-10-22 | 2005-03-10 | アムジェン インコーポレイテッド | ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法 |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| EP1462116A1 (de) * | 2003-03-29 | 2004-09-29 | Villitech SARL | Zubereitung zur Behandlung des Magen-Darm-Traktes |
| GB0307367D0 (en) * | 2003-03-29 | 2003-05-07 | Twg | Composition and method for treating the gastro-intestinal tract |
| CA2552241C (en) | 2003-12-30 | 2013-10-01 | Durect Corporation | Co-polymeric devices for controlled release of active agents |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| US9968575B2 (en) | 2012-09-27 | 2018-05-15 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
| HRP20190219T1 (hr) | 2013-11-26 | 2019-03-22 | The Children's Medical Center Corporation | Spojevi za tretman pretilosti i postupci za njihovu uporabu |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
-
1996
- 1996-08-02 AT AT96926873T patent/ATE259650T1/de not_active IP Right Cessation
- 1996-08-02 MX MX9801159A patent/MX9801159A/es not_active IP Right Cessation
- 1996-08-02 EP EP96926873A patent/EP0865294B1/de not_active Expired - Lifetime
- 1996-08-02 DK DK96926873T patent/DK0865294T3/da active
- 1996-08-02 AU AU66888/96A patent/AU6688896A/en not_active Abandoned
- 1996-08-02 WO PCT/US1996/012674 patent/WO1997006816A1/en not_active Ceased
- 1996-08-02 PT PT96926873T patent/PT865294E/pt unknown
- 1996-08-02 ES ES96926873T patent/ES2216055T3/es not_active Expired - Lifetime
- 1996-08-02 CA CA002229450A patent/CA2229450A1/en not_active Abandoned
- 1996-08-02 JP JP50931997A patent/JP4173913B2/ja not_active Expired - Fee Related
- 1996-08-02 DE DE69631605T patent/DE69631605T2/de not_active Expired - Fee Related
- 1996-08-12 ZA ZA9606798A patent/ZA966798B/xx unknown
-
2001
- 2001-05-07 US US09/850,433 patent/US20020147142A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020147142A1 (en) | 2002-10-10 |
| JPH11511165A (ja) | 1999-09-28 |
| ZA966798B (en) | 1997-02-19 |
| EP0865294A1 (de) | 1998-09-23 |
| DK0865294T3 (da) | 2004-06-28 |
| CA2229450A1 (en) | 1997-02-27 |
| MX9801159A (es) | 1998-05-31 |
| PT865294E (pt) | 2004-07-30 |
| DE69631605T2 (de) | 2005-01-05 |
| WO1997006816A1 (en) | 1997-02-27 |
| ES2216055T3 (es) | 2004-10-16 |
| JP4173913B2 (ja) | 2008-10-29 |
| EP0865294B1 (de) | 2004-02-18 |
| AU6688896A (en) | 1997-03-12 |
| DE69631605D1 (de) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69631605D1 (de) | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen | |
| ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| ATE198050T1 (de) | Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia | |
| ATE326476T1 (de) | Verfahren zur herstellung von phosphorothioat- oligomeren | |
| ATE275383T1 (de) | Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen | |
| DE69827192D1 (de) | Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen | |
| DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| ATE195527T1 (de) | Neue steroidester zur behandlung von hauterkrankungen | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| NO951761L (no) | Stabilt preparat for behandling av blodkoagulasjonssykdommer | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE510552T1 (de) | Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors | |
| ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| DE69829217D1 (de) | Vorrichtung zur therapeutischen behandlung von blutgefässen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE69522685D1 (de) | Behandlung von blut-plasma | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0865294 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |